US dealmaking has suffered its worst start to a year in a decade after policy volatility following Donald Trump’s election and escalating rhetoric over tariffs put a sudden chill on activity.

Clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis—Sionna Therapeutics (SION) priced its upsized initial public offering of ...